<DOC>
	<DOCNO>NCT02814968</DOCNO>
	<brief_summary>The aim study assess clinical utility 18F-fluoro-deoxyglucose Positron Emission Tomography ( PET ) /Computed Tomography ( CT ) Whole Body Magnetic Resonance Imaging ( MRI ) versus conventional bone scan prostate-specific antigen ( PSA ) measurement response prediction treatment Enzalutamide castration-resistant prostate cancer patient . The study assess 2 image modality perform compare traditional serial PSA measurement bone scan assess metastatic tumour load , progressive disease response treatment Enzalutamide castration-resistant prostate cancer patient . In addition measurement serially collect circulate tumour cell ( CTC ) sample , cell-free tumour DNA RNA perform order evaluate predictive value term response measurement .</brief_summary>
	<brief_title>18F-FDG PET/CT Whole Body MRI Staging Response Prediction Castration-resistant Prostate Cancer Patients Receiving Enzalutamide</brief_title>
	<detailed_description>Castration-resistant prostate cancer patient eligible 2nd line hormonal treatment undergo treatment Enzalutamide ( XTANDI ) . Subjects receive 1dd 160 mg Enzalutamide orally continuously progressive disease occur . All subject undergo 18F-FDG PET/CT scan baseline , 2 week , 2 6 , 9 12 month start androgen receptor-directed treatment . All subject undergo Whole Body MRI baseline , 6 , 9 12 month . Bone scan perform baseline , 3 month , 6 12 month . PSA measure baseline every 4 week thereafter 12 month . CTC count characteristic measure baseline Enzalutamide treatment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male age 18 year old ; Histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature ; Ongoing androgen deprivation therapy GnRH analogue bilateral orchiectomy ; Three consecutive rise PSA , 1 week apart , result two 50 % increase nadir , PSA least &gt; 5 ng/mL preferably &gt; 10 ng/mL ; Progressive disease define rise PSA level plus evidence progressive measurable soft tissue bone disease 18FFDG PET/CT , Whole Body MRI ; Castrate serum level testosterone &lt; 50 ng/dL &lt; 1.7 nmol/L ; Antiandrogen withdrawal least 6 week bicalutamide , nilutamide flutamide least 6 week ; No prior treatment cytotoxic chemotherapy ; Eastern Cooperative Oncology Group ( ECOG ) score 02 ; A life expectancy least 12 month ; Written inform consent . Severe concurrent disease , infection , comorbidity , judgment Investigator , would make patient inappropriate enrolment ; Known suspect brain metastasis active leptomeningeal disease ; History another malignancy within previous 5 year curatively treat non melanomatous skin cancer ; Total bilirubin , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 2.5 time upper limit normal Screening visit ; Creatinine &gt; 177 Âµmol/L ( 2 mg/dL ) Screening visit ; Hemoglobin &lt; 6 mmol/L , White blood cell &lt; 4.0 x10^9/L , platelet &lt; 100 x 10^9/L ; History seizure condition may predispose seizure . Also , history loss consciousness transient ischemic attack within 12 month enrolment ( Day 1 visit ) ; Contraindication MRI ( e.g . pacemaker ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Imaging</keyword>
	<keyword>PET/CT</keyword>
	<keyword>Whole body MRI</keyword>
	<keyword>Circulating tumour cell</keyword>
	<keyword>Cell-free tumour DNA</keyword>
</DOC>